AR037260A1 - Formulaciones de proteinas de liberacion sostenida acuosas - Google Patents

Formulaciones de proteinas de liberacion sostenida acuosas

Info

Publication number
AR037260A1
AR037260A1 ARP020104235A ARP020104235A AR037260A1 AR 037260 A1 AR037260 A1 AR 037260A1 AR P020104235 A ARP020104235 A AR P020104235A AR P020104235 A ARP020104235 A AR P020104235A AR 037260 A1 AR037260 A1 AR 037260A1
Authority
AR
Argentina
Prior art keywords
formulations
range
sustained release
release proteins
daltons
Prior art date
Application number
ARP020104235A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of AR037260A1 publication Critical patent/AR037260A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulaciones farmacéuticas de liberación sostenida de proteínas terapéuticasque contienen polímero de carboximetilétercelulosa y métodos de fabricación y uso de las mismas. Reivindicación 1: Una formulación farmacéutica que comprende: a) una cantidad farmacéuticamente activa de eritropoyetina; b) un agente de tamponación del pH farmacéuticamente aceptable para proporcionar un pH en un rango de aproximadamente pH 6 a aproximadamente pH9; c) un agente de la tonicidad en un rango de concentración de aproximadamente 0 a aproximadamente 200 milimolares; y d) carboximetilétercelulosa sódica en un rango de concentración de aproximadamente 0,5% a aproximadamente 7% en peso de formulación total, teniendo dicha CMC un peso molecular en un rango de aproximadamente 50.000 daltons a aproximadamente 1.000.000 daltons.
ARP020104235A 2001-11-07 2002-11-06 Formulaciones de proteinas de liberacion sostenida acuosas AR037260A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/037,369 US6818613B2 (en) 2001-11-07 2001-11-07 Aqueous sustained-release formulations of proteins

Publications (1)

Publication Number Publication Date
AR037260A1 true AR037260A1 (es) 2004-11-03

Family

ID=21893975

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104235A AR037260A1 (es) 2001-11-07 2002-11-06 Formulaciones de proteinas de liberacion sostenida acuosas

Country Status (20)

Country Link
US (3) US6818613B2 (es)
EP (1) EP1441771B1 (es)
JP (1) JP2005514394A (es)
CN (1) CN1612752A (es)
AR (1) AR037260A1 (es)
AT (1) ATE407701T1 (es)
AU (1) AU2002343666B2 (es)
BR (1) BR0213992A (es)
CA (1) CA2465890A1 (es)
CY (1) CY1110271T1 (es)
DE (1) DE60228864D1 (es)
DK (1) DK1441771T3 (es)
ES (1) ES2312633T3 (es)
HK (1) HK1066468A1 (es)
MX (1) MXPA04004367A (es)
MY (1) MY136952A (es)
PT (1) PT1441771E (es)
SI (1) SI1441771T1 (es)
TW (1) TWI332845B (es)
WO (1) WO2003053471A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1311285T4 (en) * 2000-05-15 2017-07-24 Hoffmann La Roche Liquid pharmaceutical composition containing an erythropoietin derivative
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
JP4980048B2 (ja) * 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
RU2407751C2 (ru) 2004-10-27 2010-12-27 Юниверсити Оф Денвер Аналоги адренокортикотропного гормона и относящиеся к ним методы
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
EP1988920A1 (en) * 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
CN101400367A (zh) * 2006-02-02 2009-04-01 瑞纳神经科学公司 施用trkb激动剂治疗不希望的重量减轻或进食障碍的方法
BRPI0809209A2 (pt) 2007-03-29 2014-09-02 Abbott Lab Anticorpos il-12 anti-humanos cristalinos
CA2683801A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
US20100172919A1 (en) * 2007-06-15 2010-07-08 Jan Grimm Noveltreatment for neurological disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2709545C (en) * 2007-12-28 2013-10-29 Heraeus Kulzer Gmbh Topical application and formulation of erythropoietin for skin wound healing
US8795345B2 (en) * 2009-07-08 2014-08-05 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8357179B2 (en) * 2009-07-08 2013-01-22 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8795317B2 (en) * 2009-07-08 2014-08-05 Concentric Medical, Inc. Embolic obstruction retrieval devices and methods
US8529596B2 (en) 2009-07-08 2013-09-10 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8357178B2 (en) * 2009-07-08 2013-01-22 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US20110009941A1 (en) * 2009-07-08 2011-01-13 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
CA2815689C (en) 2010-11-11 2016-11-22 Abbvie Biotechnology Ltd. Improved high concentration anti-tnf.alpha. antibody liquid formulations
CA2826615A1 (en) 2011-02-04 2012-08-09 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
EA026226B1 (ru) 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
TW201842929A (zh) * 2017-05-03 2018-12-16 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
EP0006227B1 (en) * 1978-06-16 1984-12-27 Kyowa Hakko Kogyo Co., Ltd Antithrombotic pharmaceutical preparation containing 2,2'-dithiobis benzamide derivatives and new 2,2'-dithiobis benzamide derivatives
EP0090837A1 (en) 1981-10-08 1983-10-12 BERG, Kurt Frimann Method and composition for treating a patient suffering from interferonsusceptible disorder
JPH0686480B2 (ja) * 1983-02-21 1994-11-02 雪印乳業株式会社 エリスロポエチン製造用モノクローナル抗体
ES8404783A1 (es) * 1983-03-21 1984-05-16 Prodes Sa Procedimiento para la obtencion del ester del acido 2-(2,6-diclorofenil)amino bencenoacetico con acido glicolico.
JPS604186A (ja) * 1983-06-21 1985-01-10 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン化合物
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4717717A (en) 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
AU705968B2 (en) * 1995-06-07 1999-06-03 Alkermes Controlled Therapeutics, Inc. Device for releasing aggregation-stabilized, biologically active agent
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
BR9707325A (pt) 1996-02-09 1999-04-13 Amgen Inc Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma
SI0964702T1 (sl) 1996-08-02 2007-02-28 Ortho Mcneil Pharm Inc Polipeptidi, ki imajo posamezen kovalentno vezan N-terminalni vodotopni polimer
DK0986644T3 (da) 1997-07-23 2007-01-29 Roche Diagnostics Gmbh Fremstilling af erythropoietin ved endogen genaktivering med virale promotorer
ES2208798T3 (es) 1997-09-01 2004-06-16 Aventis Pharma Deutschland Gmbh Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999066054A2 (en) 1998-06-15 1999-12-23 Genzyme Transgenics Corp. Erythropoietin analog-human serum albumin fusion protein
IL141688A0 (en) 1998-09-04 2002-03-10 Scios Inc Hydrogel compositions for the controlled release administration of growth factors
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
CO5160256A1 (es) 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
DK1181036T3 (da) 1999-04-09 2008-11-24 Ortho Mcneil Pharm Inc Farmaceutiske sammensætninger af erythropoietin
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins

Also Published As

Publication number Publication date
US7282480B2 (en) 2007-10-16
US6818613B2 (en) 2004-11-16
HK1066468A1 (en) 2005-03-24
EP1441771B1 (en) 2008-09-10
US20030148938A1 (en) 2003-08-07
MXPA04004367A (es) 2005-05-16
TWI332845B (en) 2010-11-11
MY136952A (en) 2008-12-31
BR0213992A (pt) 2004-08-31
ATE407701T1 (de) 2008-09-15
AU2002343666A1 (en) 2003-07-09
US20030181361A1 (en) 2003-09-25
AU2002343666B2 (en) 2007-04-05
PT1441771E (pt) 2008-10-29
TW200303215A (en) 2003-09-01
CA2465890A1 (en) 2003-07-03
CN1612752A (zh) 2005-05-04
EP1441771A1 (en) 2004-08-04
SI1441771T1 (sl) 2009-02-28
JP2005514394A (ja) 2005-05-19
CY1110271T1 (el) 2015-01-14
DE60228864D1 (de) 2008-10-23
US20050164927A1 (en) 2005-07-28
ES2312633T3 (es) 2009-03-01
DK1441771T3 (da) 2009-01-05
WO2003053471A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
AR037260A1 (es) Formulaciones de proteinas de liberacion sostenida acuosas
HRP20020880B1 (en) New pharmaceutical composition
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
DK1283700T3 (da) Farmaceutiske sustained release-præparater til parenteral administration af biologisk aktive hydrofile forbindelser
YU62096A (sh) Kontrolisano-otpuštajuća farmaceutska formulacija, korišćenje polietilen oksida u njima i postupak za njihovu proizvodnju
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
HRP20030046B1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
DE69838300D1 (de) Pharmazeutische suspensionstabletten-zusammenstellungen
CO4920214A1 (es) Composiciones que contienen tetrahidrolipstatina
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
ES2164837T3 (es) Formulacion oral de olanzapina.
IT1276689B1 (it) Forma farmaceutica solida ad uso orale
NO20030897D0 (no) Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
IT1301966B1 (it) Composizioni farmaceutiche ad attivita' analgesica
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
AR033403A1 (es) Uso de reovirus para la fabricacion de un medicamento para reducir una masa tumoral solida.
SE0102440D0 (sv) New compound
HUP0204202A2 (hu) Ibuprofent tartalmazó hatóanyag-preparátum, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
RS51677B (en) PHARMACEUTICAL COMPOSITION COVERING AMLODIPINE BEZILATE AND LISINOPRIL DIHYDRATE AND PROCEDURE FOR THEIR PREPARATION
AR043418A1 (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor
AR012868A1 (es) COMPOSICIoN FARMACÉUTICA QUE COMPRENDE UN PÉPTIDO AGONISTA DE LHRH, UN ANTAGONISTA DE LHRH O UN PÉPTIDO DE GRF Y NICOTINAMIDA.
SE8901003L (sv) Snabbloesliga preparat
EA200702496A1 (ru) Местная композиция, содержащая желатин

Legal Events

Date Code Title Description
FB Suspension of granting procedure